What is ArcScan?
ArcScan specializes in the development of advanced robotic ultrasound technology designed to revolutionize ophthalmic imaging. The company's flagship solution, the Insight 100, provides high-resolution, precise anatomical data that is critical for refractive surgery applications. By offering surgeons unparalleled clarity and detailed insights into eye anatomy, ArcScan enhances clinical confidence and optimizes patient outcomes. The firm serves a specialized market of ophthalmic surgeons and high-end practices that prioritize data-driven surgical planning and advanced diagnostic accuracy. Through its commitment to technological precision, ArcScan is effectively bridging the gap between complex imaging requirements and streamlined clinical workflows.
How much funding has ArcScan raised?
ArcScan has raised a total of $3.7M across 1 funding round:
Private Equity
$3.7M
Private Equity (2015): $3.7M, investors not publicly disclosed
Key Investors in ArcScan
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for ArcScan?
With the successful closure of this major enterprise-level funding round, ArcScan is poised to enter a new phase of commercial expansion and product development. The strategic allocation of this capital will likely focus on broadening the market reach of the Insight 100, while simultaneously investing in research and development to refine its robotic imaging capabilities. As the demand for high-precision ophthalmic care continues to rise, ArcScan is strategically aligned to capture significant market share by empowering practitioners with the tools necessary for superior treatment planning. Future growth will likely be defined by the integration of these imaging insights into broader digital health ecosystems, further cementing the company's role as a leader in the evolution of refractive surgery technology.
See full ArcScan company page
